Inquiry Basket
Loading ......
Antimicrobial resistance (AMR) has emerged as one of the most critical global health challenges, threatening the effectiveness of antibiotics and complicating the treatment of infectious diseases. The rapid evolution and dissemination of resistance determinants—particularly β-lactamases and last-line resistance mechanisms—have significantly reduced the clinical utility of many antimicrobial agents, including carbapenems and colistin.
To address these challenges, the Coherent AMR Solution Portfolio offers a comprehensive suite of recombinant antimicrobial resistance proteins. This platform is designed to support diagnostic development, therapeutic research, and mechanistic studies by providing highly characterized, reproducible, and application-ready protein reagents.
The Coherent AMR Solution Portfolio is an integrated collection of recombinant proteins representing the most significant antimicrobial resistance determinants found in clinically relevant bacterial pathogens. These proteins include multiple classes of β-lactamases, as well as non-enzymatic resistance factors and bacterial toxins.
Unlike traditional pathogen-derived materials, these recombinant proteins are produced under controlled conditions, ensuring:
The portfolio encompasses key resistance mechanisms, including:
By consolidating these critical targets into a single, coherent platform, this portfolio enables streamlined workflows and facilitates the development of multiplex assays and comprehensive resistance studies.
Antimicrobial resistance proteins exhibit diverse structural and mechanistic properties that underpin their ability to neutralize antibiotic activity.
A large proportion of AMR proteins are β-lactamases that catalyze the hydrolysis of β-lactam antibiotics. These enzymes:
This enzymatic activity is central to resistance in many Gram-negative pathogens.
Fig. 1 β-Lactamase-Mediated Hydrolysis Mechanism
Metallo-β-lactamases, such as NDM, VIM, and IMP, rely on zinc ions for catalytic activity. These enzymes:
Their unique catalytic mechanism makes them critical targets for next-generation inhibitor development.
AMR proteins are categorized into multiple structural classes:
This diversity necessitates a comprehensive panel approach for accurate detection and effective inhibitor screening.
MCR-1 represents a distinct resistance mechanism involving lipid A modification in the bacterial outer membrane. This modification:
TSST-1 is a potent superantigen that:
Fig. 2 TSST-1 (Toxic Shock Syndrome Toxin-1)-Mediated T Cell Activation
To enhance usability and facilitate targeted applications, the portfolio is organized into several specialized panels.
Carbapenem resistance is a major concern in clinical microbiology due to its association with multidrug-resistant organisms.
Included proteins:
| Cat_N | Product Name | Expression System |
| DAG-WT7478 | Recombinant Klebsiella pneumoniae carbapenemase (KPC) | E. coli |
| DAG-WT7479 | Recombinant New Delhi Metallo-beta-lactamase (NDM) | E. coli |
| DAG-WT7480 | Recombinant Verona Integron-encoded Metallo-β-lactamase (VIM) | E. coli |
| DAG-WT7481 | Recombinant Metallo-β-Lactamase (IMP) | E. coli |
| DAG-WT7482 | Recombinant Oxacillinase-23 (OXA-23) | E. coli |
| DAG-WT7483 | Recombinant Oxacillinase-48 (OXA-48) | E. coli |
| DAG-WT7484 | Recombinant Oxacillinase-163 (OXA-163) | E. coli |
Features:
ESBL enzymes are widely distributed and contribute significantly to antibiotic resistance.
Included proteins:
| Cat_N | Product Name | Expression System |
| DAG-WT7485 | Recombinant Cefotaximase-M (CTX-M) | E. coli |
| DAG-WT7486 | Recombinant Temoniera β-Lactamase (TEM) | E. coli |
| DAG-WT7487 | Recombinant Sulfhydryl Variable β-Lactamase-1 (SHV-1) | E. coli |
Applications:
AmpC enzymes confer resistance to cephalosporins and are often underdiagnosed.
Included proteins:
| Cat_N | Product Name | Expression System |
| DAG-WT7488 | Recombinant Class C β-Lactamase (AmpC) | E. coli |
| DAG-WT7489 | Recombinant CMY-type β-lactamase (CMY-2) | E. coli |
Applications:
Included protein:
| Cat_N | Product Name | Expression System |
| DAG-WT7490 | Recombinant Mobilized Colistin Resistance Protein-1 (MCR-1) | E. coli |
Significance:
Included protein:
| Cat_N | Product Name | Expression System |
| DAG-WT6239 | Recombinant S. aureus Toxic Shock Syndrome Toxin-1 (TSST-1) [His] | E. coli |
Applications:
The portfolio supports a wide spectrum of applications across multiple disciplines.
Recombinant AMR proteins are essential for developing:
They serve as:
These proteins are widely used as immunogens for:
AMR proteins play a critical role in:
Applications include:
Standardized proteins support:
TSST-1 enables:
This portfolio includes all major classes of AMR determinants, enabling:
Recombinant production ensures:
Products are tailored for:
Production pipelines support both research and commercial-scale needs.
Targets included in this portfolio are directly associated with:
They are used in diagnostics, antibody development, drug discovery, and resistance mechanism studies.
No. These recombinant proteins are non-infectious and safe to handle under standard laboratory conditions.
The portfolio includes carbapenemases, ESBLs, AmpC enzymes, colistin resistance, and bacterial toxins.
Yes. Many of these proteins are enzymatically active and suitable for inhibitor screening and kinetic analysis.
Yes. Custom protein expression, purification, and assay development services are available upon request.
The Coherent AMR Solution Portfolio represents a unified and strategically designed platform to address the escalating global challenge of antimicrobial resistance. By integrating key resistance determinants into a single, application-focused offering, this portfolio empowers researchers and developers to accelerate innovation in diagnostics, therapeutics, and surveillance.
With its combination of scientific rigor, comprehensive coverage, and application versatility, this portfolio provides essential tools for advancing the understanding of resistance mechanisms and supporting the global effort to combat drug-resistant infections.
References
Loading ......
